GLP-1 users may be making a major weight-loss mistake, new study suggests
Research presented at ENDO 2026 indicates that individuals using GLP-1 medications for weight loss often become less active. Experts suggest that strength training and protein intake are essential to prevent muscle loss. This trend may be linked to accelerated cellular aging.
What changed
Recent reports highlight the specific need for protein and strength training to counter muscle loss.
Live updates
-
ENDO 2026 Study Links GLP-1 Use to Reduced Physical Activity
confidence 90%Research presented at ENDO 2026 indicates that individuals using GLP-1 medications for weight loss often become less active. Experts suggest that strength training and protein intake are essential to prevent muscle loss. This trend may be linked to accelerated cellular aging.
What's confirmed:
- An ENDO 2026 study found that many GLP-1 users become less active after starting treatment.
- Decreased activity levels among GLP-1 users include a drop in daily step counts.
Still unconfirmed:
- GLP-1 muscle loss may accelerate cellular aging.
- Semaglutide and tirzepatide have become standard obesity treatments in Canada this year.
-
GLP-1 Users Reducing Physical Activity After Starting Medication
confidence 90%Research presented at ENDO 2026 shows adults using GLP-1 drugs for weight loss significantly decrease their exercise. This decline includes a drop in daily step counts. Experts warn that these habits increase the risk of muscle loss.
What's confirmed:
- Adults using GLP-1 medications for weight loss significantly reduce their physical activity.
- Daily steps and exercise decline after patients start weight loss medication.
Still unconfirmed:
- Testosterone levels may increase or stabilize in people taking GLP-1 medications.
-
GLP-1 Users Show Significant Decline in Physical Activity
confidence 100%A new study presented at ENDO 2026 indicates that adults using GLP-1 drugs for weight loss are reducing their exercise and movement. Researchers warn that this trend increases the risk of muscle loss. Experts advise that physical activity should be viewed as essential rather than optional for these patients.
What's confirmed:
- Adults using GLP-1 medications for weight loss tend to exercise less after starting the drugs.
- An ENDO 2026 study of 753 users found daily steps dropped by 560 and exercise fell by 6 minutes per day after starting Ozempic or Wegovy.
- GLP-1 drugs including semaglutide, liraglutide, dulaglutide, and tirzepatide reduce both lean muscle mass and fat.
- The decline in physical activity among GLP-1 users raises concerns regarding long-term health and muscle loss.